Revenue Growth: 7.6% in local currency for the full year. EBITA Growth: 7.4% in local currency, with a 16% increase in the second half. EBITA Margin Improvement: 130 basis points year-over-year for the second half. Adjusted EBITDA Margin Increase: 600 basis points from first half to second half. Net Debt-to-EBITDA Ratio: 1.2, well within the target range. Cash Flow Improvement: Operational free cash flow increased by 7.2% to CHF 578 million. Hearing Instruments Growth: 8.5% for the year, with 9.8% in the second half. Audiological Care Growth: 8.1% in the second half. Cochlear Implants System Sales Growth: 16.3% for the full year. Gross Margin: Improved by 30 basis points in local currency. OpEx Growth: Reduced from above 10% to 6.2% in the second half. Dividend Increase: Proposed increase to CHF 4.40 from CHF 4.30 last year. Guidance for Next Fiscal Year: Revenue growth of 5% to 9% and EBITA growth of 11% to 15% adjusted.

Warning! GuruFocus has detected 2 Warning Sign with TBVPF.

Release Date: May 09, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

Sonova Holding AG (SONVF) reported solid growth with market share gains across all four business segments. The hearing instruments segment showed strong growth, particularly driven by the Infinio Sphere product, which received positive customer feedback. The company achieved a significant improvement in EBITDA margin, with a 600 basis point increase from the first half to the second half of the fiscal year. Sonova Holding AG (SONVF) successfully implemented structural changes, resulting in a CHF40 million reduction in operating expenses. The cochlear implants business experienced a 16.3% growth in system sales, indicating strong market acceptance and customer confidence in product quality.

Negative Points

The global market, particularly in the US, experienced a slowdown, with growth dropping to around 2%, impacting overall revenue growth. There were concerns about the sustainability of market share gains due to new product launches by competitors. The company faced challenges with tariff impacts on the cochlear implants and consumer hearing business, particularly in the US and China. Sonova Holding AG (SONVF) had to implement restructuring costs, which were higher than initially communicated, impacting short-term financials. The audiological care segment experienced revenue weakness in the first half of the fiscal year, necessitating focused efforts on lead generation and cost management.

Q & A Highlights

Q: Can you unpack the guidance for fiscal year '25-'26, particularly regarding pricing impacts and market assumptions? A: We anticipate a slight positive pricing impact in the first half of the year, normalizing in the second half. We've factored in a potential return to Costco and a meaningful price increase in the VA contract, which only adjusts prices every five years. The guidance assumes a 1% to 3% market growth, with significant contributions from new product launches and market share gains.

Story Continues

Q: How did the US market perform recently, and what are your expectations? A: The US market showed a return to positive growth in April after a negative trend in February and March. We observed a pattern similar to 2021, where new customer acquisition continued but existing customers delayed purchases. We expect the US market to remain more muted compared to Europe, impacting ASP due to geographic mix.

Q: What are the key drivers for your expected margin expansion this year? A: The margin expansion is driven by structural cost improvements, including a CHF40 million reduction in OpEx, and a better cost structure. We also expect benefits from new product launches and continued market share gains. The first half of the year will see more significant improvements due to these factors.

Q: Can you elaborate on the expected growth in the cochlear implant segment and any potential impacts from competitor launches? A: We expect continued growth in cochlear implants, primarily driven by volume. While competitor launches are noted, we believe our product offerings and market strategies will sustain growth. The recent CDC cuts to pediatric screening are not expected to significantly impact our revenue.

Q: How are you addressing potential tariff impacts on your business? A: We have factored in current tariff rates into our guidance, particularly for Cochlear Implants to China and Consumer Hearing products to the US. We are exploring mitigation strategies, including shifting some manufacturing to other countries and increasing prices where feasible. Our long-term strategy includes diversifying manufacturing locations to reduce tariff exposure.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

This article first appeared on GuruFocus.

View Comments